Disposable syringes market seen reaching $18.02 billion by 2030

The Business Research Company says the disposable syringes market will rise from $12.51 billion in 2025 to $13.42 billion in 2026, then climb to $18.02 billion by 2030. Growth is being driven by vaccination programs, injectable medications, safety-focused product design and rising healthcare demand in emerging markets.

Why it matters: - Disposable syringes are a core tool for vaccines, insulin and other injectable drugs, so demand tracks broader healthcare activity. - The market’s projected growth points to stronger need for infection control, safer injection practices and higher-volume medical manufacturing. - The shift toward safety-engineered and auto-disable syringes could reduce needlestick injuries and cross-contamination risks.

What happened: - The Business Research Company released a market study on disposable syringes on Aug. 5, 2026. - The report says the market will grow from $12.51 billion in 2025 to $13.42 billion in 2026, a 7.3% compound annual growth rate. - The report forecasts the market will reach $18.02 billion by 2030, at a 7.6% CAGR. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Disposable syringes are single-use medical instruments, mostly made from plastic, used for injection administration or fluid aspiration. - Disposable syringes are typically sold in sizes from 1 ml to 10 ml. - The products may come with or without pre-attached needles. - Their single-use design lowers the risk of cross-contamination and transmission of infectious diseases. - The market’s recent expansion has been driven by vaccination programs, broader use of disposable medical devices, healthcare infrastructure growth, treatment for chronic illness and lower-cost plastic syringes. - Future growth is expected to be supported by investment in vaccination readiness, concern over needlestick injuries, pharmaceutical manufacturing growth, demand in emerging healthcare economies and syringe safety innovation. - The report flags growing use of safety-engineered syringes, rising demand for auto-disable syringes, stronger infection control measures, mass immunization efforts and more efficient high-volume production as major trends. - Injectable medications remain a key demand driver because they are used to treat conditions including diabetes, hypertension and cancer. - In July 2024, the Australian Institute of Health and Welfare reported that 37% of surveyed individuals named heroin as their most commonly injected drug in 2023, up from 35% in 2022. - The same data showed methamphetamine use among participants at 56% in 2023, compared with 54% in 2022. - The report says that sustained demand for injectable drug administration supports disposable syringe demand. - The report also says 2026 market coverage now includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and future trend analysis.

Between the lines: - The market outlook reflects a mix of public health policy, pharmaceutical production and device safety priorities. - Growth in auto-disable and safety-engineered syringes suggests buyers are prioritizing safer handling over basic cost alone. - Fastest growth in Asia-Pacific signals that new healthcare spending and immunization programs may be shifting demand beyond mature markets.

What's next: - The market is expected to keep expanding through 2030 as vaccination and injectable-treatment demand rises. - Product innovation around needle safety and infection control is likely to remain central to competition. - The full report and sample are available through the company’s market report page and sample download.

The bottom line: - Disposable syringes are on a steady growth path, with healthcare demand, safety features and immunization programs shaping the next phase of the market.